| Bioactivity | LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies[1]. |
| Invitro | LETC 抑制转染的 DH60.21 神经母细胞瘤细胞中的 α-syn 聚集，EC50 为 66 nM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LETC 相关抗体: |
| In Vivo | LETC（10 mg/kg；口服；每周 5 天；持续 6 周）显著减少多个脑区 α-Syn 阳性神经元，从而挽救了这些小鼠在开放场中的运动缺陷。LETC 不会改善家笼环境中 L62 小鼠的活动缺陷[1]。在 α-Syn 转基因 L62 小鼠中，口服给药后 LETC 在脑中积累，半衰期约为 6 小时[1]。在 L62 小鼠中单次口服 LETC (15 mg/kg) 后获得的药代动力学参数。1.19 parameter |
| Formula | C20H29Cl2N3S |
| Molar Mass | 414.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karima Schwab, et al. LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy. Eur J Pharmacol. 2024 May 5:970:176505. |